Literature DB >> 18305353

Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities.

Atsushi Fukumoto1, Yong-Pil Kim, Hideaki Hanaki, Kazuro Shiomi, Hiroshi Tomoda, Satoshi Omura.   

Abstract

Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 microg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to beta-lactam antibiotics. Furthermore, among beta-lactam antibiotics, the activity of carbapenems was most remarkably potentiated by cyslabdan.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18305353     DOI： 10.1038/ja.2008.102

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  13 in total

Review 1.  Streptomycetes: Surrogate hosts for the genetic manipulation of biosynthetic gene clusters and production of natural products.

Authors:  Keshav K Nepal; Guojun Wang
Journal:  Biotechnol Adv       Date:  2018-10-09       Impact factor: 14.227

Review 2.  Bacterial diterpene synthases: new opportunities for mechanistic enzymology and engineered biosynthesis.

Authors:  Michael J Smanski; Ryan M Peterson; Sheng-Xiong Huang; Ben Shen
Journal:  Curr Opin Chem Biol       Date:  2012-03-22       Impact factor: 8.822

3.  Systems-level antimicrobial drug and drug synergy discovery.

Authors:  Terry Roemer; Charles Boone
Journal:  Nat Chem Biol       Date:  2013-04       Impact factor: 15.040

4.  Natural lipopeptide antibiotic tripropeptin C revitalizes and synergistically potentiates the activity of beta-lactams against methicillin-resistant Staphylococcus aureus.

Authors:  Hideki Hashizume; Yoshiaki Takahashi; Shigeko Harada; Akio Nomoto
Journal:  J Antibiot (Tokyo)       Date:  2015-01-14       Impact factor: 2.649

5.  Peptidoglycan Cross-Linking Preferences of Staphylococcus aureus Penicillin-Binding Proteins Have Implications for Treating MRSA Infections.

Authors:  Veerasak Srisuknimit; Yuan Qiao; Kaitlin Schaefer; Daniel Kahne; Suzanne Walker
Journal:  J Am Chem Soc       Date:  2017-07-11       Impact factor: 15.419

6.  Streptomyces lactacystinicus sp. nov. and Streptomyces cyslabdanicus sp. nov., producing lactacystin and cyslabdan, respectively.

Authors:  Akira Také; Atsuko Matsumoto; Satoshi Ōmura; Yōko Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2014-12-10       Impact factor: 2.649

7.  Biosynthesis of mercapturic acid derivative of the labdane-type diterpene, cyslabdan that potentiates imipenem activity against methicillin-resistant Staphylococcus aureus: cyslabdan is generated by mycothiol-mediated xenobiotic detoxification.

Authors:  Haruo Ikeda; Kazuo Shin-Ya; Tohru Nagamitsu; Hiroshi Tomoda
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-27       Impact factor: 3.346

8.  The nonantibiotic small molecule cyslabdan enhances the potency of β-lactams against MRSA by inhibiting pentaglycine interpeptide bridge synthesis.

Authors:  Nobuhiro Koyama; Yuriko Tokura; Daniela Münch; Hans-Georg Sahl; Tanja Schneider; Yoshio Shibagaki; Haruo Ikeda; Hiroshi Tomoda
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

Review 9.  Bacterial terpenome.

Authors:  Jeffrey D Rudolf; Tyler A Alsup; Baofu Xu; Zining Li
Journal:  Nat Prod Rep       Date:  2021-05-26       Impact factor: 15.111

10.  Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity.

Authors:  Michael Stenger; Carsten Behr-Rasmussen; Kasper Klein; Rasmus B Grønnemose; Thomas Emil Andersen; Janne K Klitgaard; Hans Jørn Kolmos; Jes S Lindholt
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.